title: Rosuvastatin lowers coenzyme Q10 levels, but not mitochondrial adenosine triphosphate synthesis, in children with familial hypercholesterolemia.
abstract: OBJECTIVE
  To investigate whether statin therapy affects coenzyme Q10 (CoQ10) status in children with heterozygous familial hypercholesterolemia (FH).
  
  
  METHODS
  Samples were obtained at baseline (treatment naïve) and after dose titration with rosuvastatin, aiming for a low-density lipoprotein cholesterol level of 110 mg/dL. Twenty-nine patients were treated with 5, 10, or 20 mg of rosuvastatin for a mean period of 29 weeks.
  
  
  RESULTS
  We found a significant (32%) decrease in peripheral blood mononuclear cell (PBMC) CoQ10 level (P = .02), but no change in PBMC adenosine triphosphate synthesis (P = .60). Uncorrected plasma CoQ10 values were decreased significantly, by 45% (P < .01). In contrast, ratios of plasma CoQ10/total cholesterol and CoQ10/low-density lipoprotein cholesterol remained equal during treatment.
  
  
  CONCLUSIONS
  In children with FH, rosuvastatin causes a significant decrease in cellular PBMC CoQ10 status but does not affect mitochondrial adenosine triphosphate synthesis in children with FH. Further studies should address whether (rare) side effects of statin therapy could be explained by a deterioration in CoQ10 status.
authors.affiliation: Department of Pediatrics, Academic Medical Center, Amsterdam, The Netherlands.
authors.forename: Hans J
authors.initials: HJ
authors.lastname: Avis
authors.forename: Ian P
authors.initials: IP
authors.lastname: Hargreaves
authors.forename: Jos P N
authors.initials: JP
authors.lastname: Ruiter
authors.forename: John M
authors.initials: JM
authors.lastname: Land
authors.forename: Ronald J
authors.initials: RJ
authors.lastname: Wanders
authors.forename: Frits A
authors.initials: FA
authors.lastname: Wijburg
mesh_terms: D000255:Adenosine Triphosphate / Q000096:biosynthesis*; D000293:Adolescent; D002648:Child; D002784:Cholesterol / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005464:Fluorobenzenes / Q000494:pharmacology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008928:Mitochondria / Q000378:metabolism; D009426:Netherlands; D011743:Pyrimidines / Q000494:pharmacology*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000494:pharmacology*; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000097:blood / Q000187:drug effects
chemical_list: D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D014451:Ubiquinone; D000068718:Rosuvastatin Calcium; D000255:Adenosine Triphosphate; D002784:Cholesterol; C024989:coenzyme Q10